documents: FDA-2022-N-2390-0041

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2022-N-2390-0041 FDA FDA-2022-N-2390 Memorandum - Separation of Functions; Proposal to Refuse to Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon) (sNDA 205677-012) Other Memorandum 2024-09-04T04:00:00Z 2024 9 2024-09-04T04:00:00Z   2024-09-04T16:14:53Z   0 0 09000064866c0cf3

Links from other tables